Mutation Screening of TFG in α-Synucleinopathy and Amyotrophic Lateral Sclerosis

Mov Disord. 2022 Aug;37(8):1756-1761. doi: 10.1002/mds.29079. Epub 2022 May 31.

Abstract

Background: Recently, p.R383H in TFG was identified as the disease cause in a family with α-synucleinopathy and amyotrophic lateral sclerosis (ALS). However, no further replication has been conducted in larger cohorts.

Objective: The aim was to explore the genetic role of TFG in α-synucleinopathy and ALS.

Methods: We analyzed the rare protein-coding variants in patients with Parkinson's disease (PD), ALS, multiple system atrophy (MSA), spastic paraplegia (N = 2709), and 7536 controls with whole-exome sequencing.

Results: Nine rare variants were identified in PD and two in MSA. One PD patient carried the same variant p.R383H. Similarly, this patient developed early-onset PD with bradykinesia and rigidity on the left side as the initial symptoms. However, at the gene level, rare variants of TFG were not enriched in patients.

Conclusions: Rare variants of TFG were not enriched in α-synucleinopathy and ALS. However, we could not deny the potential pathogenicity of specific variants such as p.R383H. Further exploration is still necessary. © 2022 International Parkinson and Movement Disorder Society.

Keywords: TFG; Parkinson's disease; rare variant.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amyotrophic Lateral Sclerosis* / genetics
  • Genetic Predisposition to Disease
  • Humans
  • Multiple System Atrophy* / genetics
  • Mutation / genetics
  • Parkinson Disease* / genetics
  • Proteins* / genetics
  • Synucleinopathies* / genetics

Substances

  • Proteins
  • TFG protein, human